# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Chardan Capital analyst Geulah Livshits maintains 4D Molecular Therapeutics (NASDAQ:FDMT) with a Buy and maintains $38 price...
4D Molecular Therapeutics reports 24-week interim data from its PRISM Phase 2 trial, showing 77% of wet AMD patients injection-...
4D Molecular Therapeutics (NASDAQ:FDMT, 4DMT or the Company)))), a leading clinical-stage genetic medicines company focused on ...
RBC Capital analyst Luca Issi reiterates 4D Molecular Therapeutics (NASDAQ:FDMT) with a Outperform and maintains $40 price t...
4D-175 comprises the proprietary low-dose intravitreal R100 AAV vector and a codon-optimized transgene encoding a highly functi...
24-week landmark safety and clinical activity data for 45 patients enrolled in the Population Extension cohort expected to be p...
Injection-free subgroup results demonstrated that a single intravitreal dose of 4D-150 without any supplemental anti-VEGF inj...